Full Press Release Details
MINNEAPOLIS , Nov. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene. The AmplideX ® PCR/CE CFTR Kit, intended for research use only, provides broader coverage of the diverse U.S. population 1,2 than any other commercially available, targeted CFTR testing assay.
Cystic fibrosis is a life-limiting, autosomal recessive disease caused by variants in the CFTR gene. Many people with cystic fibrosis experience problems with their lungs, including serious infections, limited function, and long-term damage.
While much is known about variants associated with cystic fibrosis, the vast majority of that information came from studies of people of European descent. As a result, screening and diagnostic tests, as well as research-use assays, are more likely to detect pathogenic variants in individuals of European descent and less likely to detect them in individuals with non-European ancestry 3 .
"We are committed to ensuring that our Asuragen kits consistently deliver the most reliable information across all populations. To that end, we are proud to launch the new AmplideX PCR/CE CFTR Kit, which incorporates variants from the latest large-scale studies of diverse populations to provide significantly broader coverage," said Kim Kelderman , President, Diagnostics and Genomics Segment.
Because it includes variants identified in recent population genomics studies, the AmplideX PCR/CE CFTR Kit is designed to detect approximately 93% of CFTR pathogenic variants 4 observed in the U.S. population, providing more reliable variant detection regardless of ancestry. It can identify a broad range of variant types, including copy number variants, single tandem repeats, single nucleotide polymorphisms, insertions, and deletions. The kit can also resolve variant zygosity.
The assay uses a simple, streamlined, and scalable approach to deliver results in less than five hours with fewer hands-on steps than other CFTR assays. It is optimized for use on commonly used PCR and capillary electrophoresis laboratory equipment. The assay also includes push-button data analysis software and shares a common workflow with other assays in the AmplideX product portfolio for easy implementation. Finally, the AmplideX PCR/CE CFTR Kit can also combine with Asuragen's AmplideX ® PCR/CE FMR1 Kit and AmplideX ® PCR/CE SMN1/2 Plus Kit to provide the first-ever same-platform assay solution for this trio of the most prevalent and commonly analyzed carrier genes.
To learn more about this latest addition to the AmplideX portfolio, please visit www.asuragen.com/CFTR .
About Bio-Techne Corporation (NASDAQ: TECH )
Contact: David Clair , Senior Director, Investor Relations & Corporate Development [email protected] 612-656-4416
SOURCE Bio-Techne Corporation